CDRH Focusing On New PMA Pathway, Clinical Trials Program In 2014/2015 Priorities

CDRH Director Jeffrey Shuren discussed the device center’s two-year strategic priorities with “The Gray Sheet.” The center plans to rebalance pre-market and post-market data collection, when appropriate, and improve the processes for starting up clinical trials in the U.S.

FDA’s device center plans to establish a new PMA pathway for high-risk devices for unmet medical needs and appoint a new director to oversee the pre-market clinical trials program. The plans are part of CDRH’s 2014 and 2015 strategic priorities, released Feb. 5.

This is the first time the device center has released a two-year strategic plan rather than just an annual plan

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Regulation

More from Policy & Regulation